AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ventilator Associated Pneumonia (VAP) Pipeline Review, H1 2019 - ResearchAndMarkets.com

May 22, 2019

DUBLIN--(BUSINESS WIRE)--May 22, 2019--

The “Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 4, 8, 8, 1 and 1 respectively.

Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

Companies Mentioned

  • Aridis Pharmaceuticals Inc
  • AstraZeneca Plc
  • Cumberland Pharmaceuticals Inc
  • CytaCoat AB
  • Destiny Pharma Plc
  • Dong-A Socio Holdings Co Ltd
  • Evaxion Biotech ApS
  • MedImmune LLC
  • Meiji Seika Pharma Co Ltd
  • Merck & Co Inc
  • Motif Bio Plc
  • Nabriva Therapeutics Plc
  • Polyphor AG
  • Shionogi & Co Ltd
  • Spero Therapeutics Inc
  • Tetraphase Pharmaceuticals Inc
  • Wockhardt Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bvccsn

View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005680/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Infectious Diseases Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/22/2019 12:48 PM/DISC: 05/22/2019 12:48 PM

http://www.businesswire.com/news/home/20190522005680/en

All contents © copyright 2019 The Associated Press.All rights reserved.